ARTICLE | Finance
Stop SINE
With $48M, Karyopharm looks to advance cancer compound through pivotal trials
May 27, 2013 7:00 AM UTC
Karyopharm Therapeutics Inc. hopes to advance lead compound KPT-330 through pivotal trials for at least two cancer indications with funds from last week's $48.2 million series B round.
An undisclosed private investor led the round, with participation from new investor Delphi Ventures and additional undisclosed investors. Karyopharm now has raised just over $80 million...